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Introduction
Taurine (TAU) plays a role in a wide variety of physi-
ological functions and is found in many tissues (Schaffer 
et al. 2010). Relatively few studies have however, explored 
its role in human physiological interventions. Taurine is 
abundant in skeletal muscle (Pierno et al. 2012), but its 
specific function is not currently fully understood. It has 
been suggested that TAU plays a role in aerobic exercise 
(Ward et al. 1999) and mitochondrial function (Hansen 
et al. 2010) since higher concentrations have been reported 
in the skeletal muscle of trained (~64 mmol kg−1 dw) vs. 
untrained (~50 mmol kg−1 dw) participants (Graham 
et al. 1995). In addition, Harris et al. (1998) have reported 
the TAU content of Type I muscle fibres of the vastus lat-
eralis to be 39.2 ± 17.8 mmol kg−1 dw compared to 
9.6 ± 2.6 mmol kg−1 dw in the Type II fibres of humans. In 
rats, higher concentrations of TAU have also been reported 
in the soleus compared to the gastrocnemius muscles 
(Matsuzaki et al. 2002), likely due to a higher proportion 
of Type I fibres usually observed in the soleus. In spite of 
there being some suggestions relating to the function of 
TAU, it remains unclear how different skeletal muscle fibre 
types might be affected either intra- or extracellularly by 
supplementation. Furthermore, it is also unclear how TAU 
supplementation might affect exercise performance in 
activities which recruit different proportions of either type I 
or type II fibres. The lack of observed increases in skeletal 
muscle TAU content with supplementation, suggest that it 
is the alterations to extracellular TAU concentration that 
Abstract Taurine (TAU) has been shown to improve exer-
cise time to exhaustion and 3-km running performance; 
however, no studies have considered the effect of acute 
TAU ingestion on short duration cycling time trial (TT) 
performance. The aim of this study was to determine the 
effects of a single oral acute dose of 1000 mg of TAU on 
a laboratory simulated 4-km cycling TT. Eleven trained 
male cyclists performed three, 4-km TTs. The first of the 
trials was a familiarisation, followed by two subsequent tri-
als which were performed two hours after the consumption 
of either 1000 mg of TAU or placebo (P), using a double-
blind randomised crossover design. Capillary blood sam-
ples were obtained prior to the start and immediately after 
each TT for the measurement of lactate, pH and HCO3
−. 
There was no effect of TAU (p = 0.731, d = 0.151) on 
performance (390 ± 27 and 388 ± 21 s for TAU and P, 
respectively), nor were there any condition main effects 
for VO2, lactate, pH, or HCO3
− (p > 0.05) despite post 
TT changes in lactate (7.3 ± 2.5 mmol l−1, p < 0.001, 
d = 2.86, 7.6 ± 2.0 mmol l−1 p < 0.001, d = 3.75); pH 
(−0.255 ± 0.1, p < 0.001, d = 2.62, −0.258 ± 0.09, 
p < 0.001, d = 2.87); HCO3− (−13.58 ± 2.7 mmol l−1, 
p < 0.001, d = 5.04 vs. −13.36 ± 2.3, p < 0.001, d = 5.72 
for TAU and P, respectively). The findings of this study 
suggest that a pre-exercise dose of 1000 mg TAU offers no 
performance advantage during 4-km TT nor does it alter 
the blood buffering responses in trained cyclists.
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may explain the previously reported performance improve-
ments following acute ingestion (Balshaw et al. 2013).
In the plasma, TAU concentrations have been shown to 
increase following acute exercise (Cuisinier et al. 2001, 
2002) with a suggestion that the rate of increase is directly 
related to exercise intensity (Ward et al. 1999). Cuisinier 
et al. (2001) suggested that increases in plasma TAU may 
be the result of skeletal muscle damage since it increased 
concomitantly with plasma creatine kinase concentrations. 
Studies that have reported increases in plasma TAU during 
exercise have used trained or well-trained participants with 
VO2peak values of >50 ml kg min
−1 (Cuisinier et al. 2001, 
2002; Ward et al. 1999). In contrast, Galloway et al. (2008) 
reported that 4.98 g day−1 of TAU for 7 days had no effect 
on plasma or skeletal muscle TAU concentrations in active 
participants (VO2peak ~40 ml kg min
−1). Those studies that 
have measured muscle TAU concentrations have shown 
equivocal findings, likely the result of heterogeneous par-
ticipant populations. It has been suggested that improve-
ments in performance might be explained by either, an 
interaction between TAU and the muscle membrane, 
enhanced mitochondrial buffering (Hansen et al. 2006), or 
improved force production. These potential mechanisms 
may be mediated through increased calcium release from 
the sarcoplasmic reticulum leading to improved contractile 
filament sensitivity (Dutka et al. 2014).
The majority of studies that have investigated the role of 
exogenous TAU ingestion have used animal models with 
typically much higher doses those reported in human stud-
ies (Goodman et al. 2009). In humans, many of the previ-
ous studies that have administered exogenous TAU prior 
to exercise, have done so as part of a commercially avail-
able energy drink (Red Bull™) which also contains other 
active ingredients (Forbes et al. 2007; Alford et al. 2001; 
Geiss et al. 1994). This makes it difficult to ascertain spe-
cific responses to singularly ingested TAU. Of the human 
studies that have focused solely on TAU ingestion prior to 
exercise (Balshaw et al. 2013; Rutherford et al. 2010; Gal-
loway et al. 2008; Zhang et al. 2004), only Galloway et al. 
(2008) reported no effects on either exercise performance 
(120 min at 60 % VO2peak) or on the metabolic responses 
following prolonged TAU supplementation. Rutherford 
et al. (2010) observed increased fat oxidation rates fol-
lowing acute ingestion of 1.66 g of TAU, but this was dur-
ing a 90 min exercise bout at 65 % VO2max, that preceded 
a 5 kJ kg BM−1 time trial (TT), during which no changes 
in performance were observed. The authors postulate that 
TAU mediated increases in lipolysis, were the result of 
increased cyclic adenosine monophosphate, caused by ele-
vated adenylyl cyclase activation (Rutherford et al. 2010; 
Spriet and Whitfield 2015). Conversely, Zhang et al. (2004) 
showed improved VO2max, exercise capacity, and maxi-
mal workloads following 7 days of 6 g day−1 of TAU. The 
only study to use a TT as a sole performance criterion was 
that of Balshaw et al. (2013) who demonstrated a 1.3 % 
improvement in 3-km TT running performance in well-
trained middle distance athletes, following the acute inges-
tion of 1000 mg TAU.
Given the confounding nature of these data, it remains 
unclear how oral TAU supplementation may alter skeletal 
muscle function and improve performance. Taurine has 
previously been shown to improve lactic acid buffering 
(Nakada et al. 1991) in brain cells and intramuscularly in 
rats. However, in human exercise performance studies, post 
exercise plasma lactate has remained largely unaltered by 
TAU supplementation (Lee et al. 2003; Rutherford et al. 
2010), even in the presence of an observed improvement 
in performance (Balshaw et al. 2013). Observations such 
as these, suggest that exogenously mediated increases in 
plasma TAU concentration, may influence skeletal mus-
cle function, either by altering buffering or via changes to 
taurine flux. If these suggested mechanisms of TAU action 
are correct, short duration, high intensity exercise is of par-
ticular interest, due to its profound effects on acid–base 
balance (Fitts 2008). Taurine is frequently included as an 
active ingredient in both sport and stimulant drinks, but 
at present, no studies have considered the effects of these 
types of acute doses of TAU on short duration cycling TT 
performance. Although there is some evidence from rat 
studies to suggest that there may be improved calcium reg-
ulation in skeletal muscle (Bakker and Berg 2002), it has 
yet to be demonstrated if TAU acts to alter extracellular 
buffering during high intensity exercise in trained human 
participants. Therefore, the aims of the present study were 
(1) to determine the effects of an ecologically relevant 
acute oral dose of TAU, on a laboratory simulated 4-km 
cycling TT performance in trained cyclists and (2) to deter-
mine the effects this ingestion strategy has on blood acid–
base responses.
Method
Following ethical approval, health screening and informed 
consent, 11 male trained (De Pauw et al. 2013) cyclists 
(mean ± SD age 34.6 ± 11.5 years, height 178.1 ± 5.2 cm, 
weight 74.8 ± 6.2 kg and body fat 15.5 ± 4.6 %, train-
ing >3 h week−1 and at least 2 years’ racing experience) 
performed three, 4-km TTs on a CompuTrainer Pro cycle 
ergometer (RacerMate, Seattle, USA). The CompuTrainer 
was fitted with each participants own bicycle, which was 
then calibrated in accordance with the manufacturers 
guidelines. The cyclists were allowed to use either a road 
or TT bike, but they had to use the same machine and gear 
ratios for each trial. Participants were instructed to adopt 
a position on the handlebars which was most comfortable. 
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Using this method, 4-km laboratory TTs have previously 
been shown to have a coefficient of variation of 1.6 % 
(Altareki et al. 2009) for performance times and produce 
reliable pacing strategies (Stone et al. 2011) in simi-
lar participant populations. Body composition data were 
measured using air-displacement plethysmography (Bod-
Pod V4.2.0, Life Measurement Inc., USA). Prior to each 
TT, participants were instructed to abstain from any food 
intake in the preceding 3 h and to adhere to their normal 
nutritional intake strategy. Nutritional intake was recorded 
for the 24-h period prior to attending the initial laboratory 
visit, and replicated on each subsequent occasion. For the 
preceding 24-h period, participants were also instructed to 
avoid performing any exercise. Pre-exercise urine samples 
were obtained to measure urine osmolality using a portable 
osmometer (Osmocheck, Vitech Scientific, West Sussex, 
UK) which has previously been shown to be both valid and 
reliable (Sparks and Close 2013). This was to ensure that 
this index of hydration status was consistent prior to each 
trial.
Experimental procedures
Participants performed a standardised warm-up which 
required them to cycle at a self-selected intensity for 
5 min. This was replicated prior to each subsequent TT. 
Each laboratory session was performed at the same time 
of day to minimise the potential effects of circadian vari-
ations (Souissi et al. 2010). The first laboratory visit was a 
familiarisation TT as this has been shown to improve sub-
sequent test–retest pacing strategy reliability (Ansley et al. 
2004). This initial trial was followed by two experimental 
trials that took place between five and 7 days apart, which 
was chosen to limit the confounding effects of fatigue and 
potential changes in training status. All trials commenced 
2 h after the consumption of either a 500 ml drink con-
taining only water (Buxton still mineral water, UK), in the 
case of the familiarisation and the placebo trials, or after 
the consumption of 500 ml water containing 1000 mg of 
TAU (Acrōs Organics, Geel, Belgium). This pre-exercise 
consumption period was used to elicit peak plasma TAU 
concentrations at the start of the time trial (Galloway et al. 
2008). The placebo and TAU TTs were conducted using a 
double-blind randomised crossover design. This dose was 
chosen because it has previously been shown to improve 
high intensity running performance in well-trained runners 
(Balshaw et al. 2013) and represents the typical dose in 
many commercially available energy and stimulant drinks. 
Data were downloaded from the ergometer software at 
a frequency of 37 Hz to determine each 500 m split time, 
speed and overall performance time.
Capillary blood samples were obtained from a finger-tip 
prior to the start and immediately on completion of each 
time trial to measure blood lactate (Lactate Pro Analyser, 
Arkray Inc, Kyoto, Japan), and 100 μl was collected using 
glass clinitubes (Radiometer Medical, Brønshøj, Den-
mark) to determine pO2, pCO2, pH and HCO3
− (Radiom-
eter ABL800, Copenhagen, Denmark). Respiratory gases 
(Oxycon Pro, Jaeger, CareFusion, Hoechberg, Germany) 
and heart rate (Polar Wearlink, Polar Electro OY, Kempele, 
Finland) were also measured throughout each TT. Breath-
by-breath respiratory responses were measured continu-
ously during the trials which prevented participants from 
consuming any additional fluid during the TTs. Gas analy-
sis data were saved using 5 s averaging at each 500 m of 
the trials. During the TTs, participants were only able to 
see the total distance covered, and were blinded to all other 
performance feedback and physiological variables.
Statistical analysis
Prior to analysis, all statistical assumptions were assessed 
using standard graphical methods (Grafen and Hails 2002). 
Overall 4-km TT performance was analysed using paired 
t tests and two-way repeated measures ANOVA was used 
to analyse split speeds, oxygen uptake, and heart rate 
(condition × each 500 m of the trials). All blood sample 
parameters were analysed using two-way ANOVA (condi-
tion × sample point). Post hoc pair-wise comparisons were 
made using a Bonferroni adjustment and statistical sig-
nificance was assumed as p < 0.05. Calculations of effect 
sizes were done using Cohen’s d (Cohen 1988) for t tests 
and partial eta squared (ηp2) for ANOVA. Effect sizes were 
considered trivial (<0.20), small (0.20–0.49), moderate 
(0.50–0.79), and large ≥0.80) in accordance with conven-
tional interpretations (Cohen 1988). All data are presented 
as mean ± SD and with 95 % confidence intervals. All data 
were analysed using SPSS v22 for Windows (SPSS Inc., 
Chicago, IL, USA).
Results
There were no statistical differences in overall performance 
time (Fig. 1) either between the familiarisation trial and the 
P trial (mean difference = 4.99 s, t = 0.98, CI = −6.38, 
16.35, p = 0.35, d = 0.44) nor as a result of TAU inges-
tion (mean difference = 1.87 s, t = 0.35, CI = −9.89, 
13.63, p = 0.73, d = 0.16). The pacing strategies adopted 
in the experimental trials (Fig. 2a) were characterised by 
increases in speed over the first kilometre (CI = −3.40, 
−0.23, p = 0.03) followed by a constant speed until 3 km, 
and then an acceleration during the final kilometre between 
(CI = −1.18, −0.27, p = 0.01). Despite these differences 
in speed over the course of the TT distance there were no 
main effects for experimental condition and split speeds 
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(mean difference = 0.16 km h−1, f = 0.10, CI = −0.98, 
1.30, p = 0.76) suggesting similar pacing strategies in 
both trials. The oxygen consumption (Fig. 2b) and heart 
rate (Fig. 2c) were also unaffected by TAU administra-
tion (mean difference = 0.60 ml kg min−1, f = 2.08, 
CI = −0.33, 1.53, p = 0.18 ηp2 = 0.17 and mean differ-
ence = 1.3 b min−1, f = 2.48, CI = −0.53, 3.06, p = 0.15, 
ηp2 = 0.20, respectively), but main effects for distance 
were observed for both VO2 (mean difference from 0.5 km 
to 4.0 km = 7.32 ml kg min−1, f = 26.96, CI = 5.55, 9.58, 
p < 0.001, ηp2 = 0.90) and heart rate (mean difference from 
0.5 km to 4.0 km = 31.0 b min−1, f = 107.02, CI = 25.27, 
36.72, p < 0.001, ηp2 = 0.96).
There were no main effects for experimental condi-
tion on blood lactate (mean difference = 0.19 mmol l−1, 
f = 1.06, CI = −0.22, 0.60, p = 0.33, ηp2 = 0.10), pO2 
(mean difference = 0.10 kPa, f = 0.25, CI = −0.35, 0.56, 
p = 0.63, pη2 = 0.03), pCO2 (mean difference = 0.01 kPa, 
f = 0.01, CI = −0.26, 0.24, p = 0.93, ηp2 = 0.01), pH 
(mean difference = 0.003 pH units, f = 0.12, CI = −0.02, 
0.01, p = 0.73, ηp2 = 0.010), nor HCO3 (mean dif-
ference = 0.17 mmol l−1, f = 0.50, CI = −0.37, 0.72, 
p = 0.50, ηp2 = 0.05), but there were significant main 
effects for time on all of the blood parameters (Table 1). 
This was characterised by post exercise increases in blood 
lactate (mean difference = 7.41 mmol l−1, f = 112.72, 
CI = 5.85, 8.96, p < 0.001, ηp2 = 0.92) and pO2 (mean 
difference = 2.67 kPa, f = 148.39, CI = 2.17, 3.17, 
p < 0.001, ηp2 = 0.94). Conversely pCO2 (mean dif-
ference = −1.04 kPa, f = 155.88, CI = −1.23, −0.85, 
p < 0.001, ηp2 = 0.94) pH (mean difference = −0.26 pH 
units, f = 77.52, CI = −0.32, −0.19, p < 0.001, ηp2 = 0.89) 
and HCO3 (mean difference = −13.47 mmol l−1, 
f = 334.08, CI = −15.12, −11.83, p < 0.001, ηp2 = 0.97) 
were all significantly lowered (Table 1) following the com-
pletion of the TTs. Base excess (Table 1) was also con-
sequently unaffected by taurine ingestion (mean differ-
ence = 0.18 mEq l−1, f = 0.51, CI = −0.74, 0.38, p = 0.49, 
ηp2 = 0.05), but significant decreases were observed fol-
lowing the 4-km TTs (mean difference = −16.04 mEq l−1, 
f = 222.51, CI = −18.44, −13.65, p < 0.001, ηp2 = 0.96).
Fig. 1  Mean (±SD) overall 4-km time trial performance times
Fig. 2  Mean (±SD) cycling speed (a), oxygen cost (b) and heart rate 
(c) responses during the time trial. ǂa significant increase in speed 
from previous distance (p < 0.05); *a significant increase from the 
previous distance (p < 0.05)
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Discussion
The aim of the present study was to determine the effects 
of acute oral ingestion of 1000 mg of TAU, on short dura-
tion high intensity self-paced cycling TT performance. A 
further aim was to assess the acid–base responses to this 
supplementation strategy. Previous studies investigat-
ing the use of TAU as a potential ergogenic aid have pro-
duced equivocal findings in humans (Rutherford et al. 
2010; Balshaw et al. 2013), despite strong suggestions of 
the potential of this amino acid to influence muscle func-
tionality during exercise. Recently, TAU administration has 
been demonstrated to improve running TT performance in 
well-trained middle distance runners (Balshaw et al. 2013) 
when consumed at a time that coincides with post inges-
tion peak plasma concentrations (Galloway et al. 2008). 
Balshaw et al. (2013) were, however, unable to offer direct 
measurements of the possible mechanisms responsible 
for the improvements in performance, but suggested that 
one role for increased plasma TAU concentrations may be 
as a buffer, which has also previously been demonstrated 
in an animal model (Nakada et al. 1991). In the present 
study, a 4-km cycling TT was used as a performance cri-
terion as this produces consistent pacing strategies (Stone 
et al. 2011) and is reliable in trained cyclists (Ansley et al. 
2004). This sensitive exercise model was used to determine 
any effects of 1000 mg TAU on both performance and the 
blood buffering capacity. Prior to and following the TTs 
we measured a comprehensive range of blood parameters 
using previously validated techniques (Cembrowski et al. 
2010). As a result of these carefully selected methods, this 
is the first study to show that acute low dose TAU inges-
tion does not influence blood buffering capacity prior to, 
or in response to exercise. The present study was, however, 
unable to provide an assessment of the blood metabolite 
responses during exercise or in the muscle, which may pro-
vide a more complete evaluation of the dynamic responses 
to this type of high intensity exercise (Bangsbo et al. 1993). 
These exercise performance observations are in accord-
ance with those of Rutherford et al. (2010), who used par-
ticipants of a similar training status to the present study, but 
not those of Balshaw et al. (2013), who used athletes of a 
slightly higher training status, albeit for different exercise 
tasks. Furthermore, based on both the suggestions of Gallo-
way et al. (2008) and the associated high concentrations of 
TAU in type I muscle fibres (Matsuzaki et al. 2002; Hansen 
et al. 2006) the lack of observed performance effects in the 
present study may be explained by a combination of the 
potentially higher proportions of these fibres in the athletes 
used by Balshaw et al. (2013), and the differences in train-
ing status between the participants in these studies.
The findings of the present study suggest that any 
observed buffering effects of TAU do not manifest in the 
blood in this trained cyclist population, when 1000 mg 
TAU is acutely ingested prior to exercise. The lack of meas-
urable differences in buffering responses may be due to the 
low dose of TAU. The present findings suggest that the 
improved running performances observed by Balshaw et al. 
(2013) are unlikely to be the result of the enhanced buff-
ering capacity which they proposed. The reasons for the 
discrepancy in performance between Balshaw et al. (2013) 
and the present study remain unclear. One suggestion 
might be that this TAU ingestion strategy is more effective 
in exercise that elicits higher lactate concentrations such 
as those observed by Balshaw et al. (2013), compared to 
the present study. Exploration of the differences between 
participant populations may provide some reasons for the 
equivocal findings in human TAU studies. Interestingly, 
Balshaw et al. (2013) used younger individuals (19.9 ± 1.2 
vs. 34.6 ± 11.5 years) of a superior training status (all ath-
letes ran >72 km per week and were formally coached at 
least twice per week), and were also more homogeneous 
in nature. Furthermore, in exercise studies of TAU sup-
plementation Rutherford et al. (2010), the present study, 
and Galloway et al. (2008) have all used older participants 
(27.2 ± 1.2, 34.6 ± 11.5, and 28 ± 3 years, respectively) 
and found little or no effect of TAU on metabolism. One 
possible explanation for this may be that the lower skel-
etal muscle concentrations of TAU in younger individuals 
(Galloway et al. 2008). Yoshioka et al. (2002) observed that 
Table 1  Mean (±SD) pre and post time trial blood parameter 
responses to the experimental conditions
* Denotes significant post time trial changes (p < 0.001)
Parameter Taurine Placebo
Lactate (mmol l−1)
 Pre 0.9 ± 0.3 0.9 ± 0.5
 Post 8.2 ± 2.4* 8.6 ± 2.0*
pO2 (kPa)
 Pre 9.6 ± 0.7 9.8 ± 1.1
 Post 12.3 ± 0.8* 12.4 ± 0.6*
pCO2 (kPa)
 Pre 5.4 ± 0.3 5.3 ± 0.4
 Post 4.3 ± 0.3* 4.3 ± 0.4*
pH
 Pre 7.42 ± 0.02 7.42 ± 0.01
 Post 7.16 ± 0.1* 7.16 ± 0.08*
HCO3 (mmol l
−1)
 Pre 25.5 ± 0.1 25.2 ± 1.6
 Post 11.9 ± 2.7* 11.9 ± 2.3*
Base Excess (mEq l−1)
 Pre 1.29 ± 1.1 1.01 ± 1.6
 Post −14.84 ± 3.9* −14.96 ± 3.2*
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older rat skeletal muscle was higher in TAU content, so it 
is conceivable that exogenous supplementation such as that 
used in these exercise studies, may benefit younger indi-
viduals to a greater extent. Unfortunately, this is of course 
speculative, since it is at present unclear what mechanisms 
might be responsible for the performance increase observed 
by Balshaw et al. (2013).
Previously, evidence of a buffering response following 
intense exercise was observed in a rodent model intramus-
cularly, with a very high relative dose of taurine (Nakada 
et al. 1991). Indeed, many of the animal model studies that 
have observed favourable effects following taurine adminis-
tration have used extremely high doses relative to body mass 
(Goodman et al. 2009). Shao and Hathcock (2008) have pre-
viously suggested that intakes of 3000–10,000 mg day−1 
are safe for humans, but we chose a dose of 1000 mg as 
it presents an ecologically valid strategy. This dose may, 
however, not be sufficient enough (Hansen et al. 2006) to 
cause any modifications to acid–base balance (Kilding et al. 
2012). The previously highest doses of pre-exercise tau-
rine supplementation in humans has been 3000 mg acutely 
or 3 × 2000 mg daily (Eudy et al. 2013). Galloway et al. 
(2008) used an oral dose of 1.66 mg TAU and observed 
increased plasma taurine content of ~778 ± 139 μM, some 
13 times higher than pre-ingestion concentrations 2 h later 
in a group of untrained participants. However, they reported 
that chronic dose TAU of 5000 mg day−1 for 7 days had 
no additive effect on plasma TAU concentration nor did 
it increase muscle TAU content. Perhaps therefore, of 
even more interest, may be the exploration of a method of 
increasing muscle TAU concentrations following ingestion, 
either by reducing availability, first via dietary manipula-
tion, or by establishing a method to increase cellular uptake 
of exogenously supplemented TAU by the specific trans-
porter molecule TauT (Han et al. 2006). Interestingly, with 
endurance training there is also an increase in p53 (Hawley 
and Morton 2014) which is associated with the repression 
of TauT (Han et al. 2006). This adds a further level of com-
plexity to the task of understanding how training status and 
exercise mode might affect the effectiveness and concentra-
tion of TAU, and remains at present, unclear.
The previous work of Shao and Hathcock (2008) sug-
gests that high doses of exogenous TAU can be safely con-
sumed. Therefore, future work should investigate the effect 
of doses between 3000 and 10,000 mg day−1 either rela-
tive to body/lean mass, to establish if the amount of TAU 
ingested is a limiting factor in its effectiveness in humans. 
Future studies also need to establish more effective meth-
ods of manipulating muscle TAU content, or determine a 
specific threshold plasma concentration over which there 
might be an increase in uptake since the different uptake 
responses between rodent and human muscle might be dose 
dependent. Furthermore, continued work on the ingestion 
of this amino acid is required to determine the reasons for 
the largely equivocal findings in the existing data.
Conclusion
This is the first study to show that the acute pre-exercise 
ingestion of 1000 mg of TAU does not affect 4-km cycling 
time trial performance. Furthermore, this dose did not 
appear to alter any of the blood buffering responses either 
prior to or following high intensity exercise performance 
in trained cyclists. This suggests that previously observed 
performance changes following this particular TAU inges-
tion strategy are unlikely to be associated with a disruption 
to normal acid–base balance in this population following a 
low dose of TAU. Future work needs to address the use of 
longer duration ingestion periods or exploring mechanisms 
by which TAU concentrations in human skeletal muscle 
can be increased.
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